'Limited treatment duration and re-induction with the same regimen on progression' vs 'treatment until progression' with biweekly capecitabine + oxaliplatin +/- bevacizumab in patients (PTS) with advanced colorectal cancer (CLC): a randomised phase II study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2009
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 27 Jun 2009 Results were reported at the 11th World Congress on Gastrointestinal Cancer.
- 10 Oct 2008 New trial record.